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Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by a complex multi-factorial
pathogenesis and a great clinical polymorphism. SLE is considered to be a B cell disease in which autoantibodies are the major
players. Recently, the central role of B cells has been confirmed and it has been shown that that the relative frequency of B cells
subsets is altered in SLE patients. Conventional immunosuppressive therapies such as azathioprine, cyclophosphamide or
methotrexate, reduce disease activity and improves the patient's general health conditions. These treatments have possible side
effects; in fact they could compromise liver function, fertility and innate and adaptive immune responses. Moreover, for
unknown reasons a small group of SLE patients is refractory to immunosuppressive therapy. In these cases finding an effective
treatment becomes a challenge. The progress in therapeutic antibody technology has led to the production of a wide array of
humanized monoclonal antibodies, targeting specific cell types or pathways, initiating a new era in the treatment of autoimmune
disorders. In contrast to general immuno-suppression, the availability of drugs interfering with specific pathogenetic pathways
gives the possibility to choose therapies tailored to each disease in each patient.
© 2007 Elsevier B.V. All rights reserved.
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Systemic lupus erythematosus (SLE) is a chronic
autoimmune inflammatory disease of unknown aetiol-
ogy characterized by the presence of several autoanti-
bodies and by the anatomical and functional damage of
multiple organs. B cells play a central role in the patho-
genesis of SLE.
Little is known about the frequency of the different B
cell subsets in the peripheral blood of SLE patients and
whether alteration of these subsets might relate to dis-
ease onset and progression.
Standard therapeutic strategies, commonly using
corticosteroids and immunosuppressive drugs such as
azathioprine (AZA), cyclophosphamide (CyC) or meth-
otrexate (MTX), aim at the reduction of disease activity
and improvement of the patient's general conditions.
Recently, the advances in antibody technology and
identification of factors and pathways initiating and
maintaining autoimmune disorders allowed the genera-
tion of a variety of novel molecules: humanized mono-
clonal antibodies, fusion proteins with antagonistic
function and peptibodies, the “so called” biologic drugs.
These molecules are designed to target different B cell
subsets and/or signalling pathways involved in B-cell
activation and in the inflammatory cascade, thus hope-
fully sparing patients from the side effects due to gen-
eralised immunosuppression (Table 1).
2. Altered B cell subset in SLE
The main function of B cells is to produce antibodies
normally specific for pathogens (non-self) and in auto-
immune diseases for self-antigens. Antibodies directed
against several cellular molecules and structures are a
hallmark of SLE, which is therefore considered a B-cellTable 1
Predominant B cell abnormalities in SLE and relative biological drugs
B cell abnormalities Pathogenic mechanism
Loss of tolerance, hyperactivity Generation of autoreactive B cells
Autoantibody Immune complex
Citolysis of antigen-positive cells
Autoantigen presentation to T cells Activated autoreactive T cells
Increased cytokine production Cytokine mediated persistent
inflammation and B cell activationdisease. An additional important role for B cells has
been recently demonstrated in a mouse model for SLE.
It has been shown that the disease does not develop in
mice lacking B cells, but still occurs in animals with an
intact B-cell compartment, but unable to secrete anti-
bodies [1,2]. Thus, B cells may have an antibody-inde-
pendent role in the pathogenesis of SLE, supposedly
related to their antigen presenting function or cytokine
production.
Over the last few years many studies have reported
alterations of the relative frequency of peripheral blood
B cell subsets in SLE patients. How these alterations
relate to the disease is still a matter of debate [3,4].
In the absence of therapy and independently from
disease activity, SLE patients may have a strong lym-
phopenia or, viceversa, normal or even increased lym-
phocyte counts.
In the peripheral blood it is possible to identify four
different populations of B cells: mature-naive, IgM
memory, switched memory and transitional B cells [5].
This last subset, corresponding to recent bone marrow
emigrants, is increased in most of the patients [6] and
our own results. Circulating plasma cells are virtually
undetectable in healthy controls, but can be found in
patients with active disease.
B lymphocyte stimulator (BLyS) protein (also known
as BAFF, TALL-1, THANK, TNFSF13B, and zTNF4)
is a member of the tumour necrosis factor (TNF) ligand
superfamily. It binds with high affinity to BAFF-R ex-
pressed by all B-cell subsets. BAFF and its receptors
were initially described in the mouse. It was demon-
strated that the BAFF pathway is important in B cells
development, survival and function [7]. BAFF over
expression leads to the expansion of immature transi-
tional type II B cells (T2) in the spleen, polyclonal
hypergammaglobulinemia with increased numbers ofBiologic therapy Molecular target Current status
Anti BLyS BLyS Phase II
AMG 623 BLyS Phase I
Anti-BR3 BLyS Phase I
TACI-Ig BLyS/APRIL Phase II/III
Anti CD20 CD20 Phase III
Anti CD22 CD22 Phase III
Tolerogens Anti-DNA antibodies Phase III
(LJP394)
CTLA4Ig CD28/B7 Phase I
Anti CD40L CD40/CD40L Preclinical
Anti IL6R IL6 Preclinical
Anti IL10 IL10 Phase I
Anti IFNα Type I interferon Preclinical
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bodies (including anti-double-stranded DNA). Aged
transgenic mice present with a lupus-like disease with
circulating immune complexes and kidney Ig deposition
[8]. On the basis of these observations it has been
proposed that BAFF plays a role not only in the survival
of immature T2 B cells [9], but also in the pathogenesis
of SLE. Several studies have measured the concentra-
tion of BAFF in human autoimmune diseases and
found increased BAFF in not only SLE, but also in
Rheumatoid Arthritis, Multiple Sclerosis and Sjogren
syndrome [10]. Because SLE patients have an increase
frequency of transitional B cells and plasma cells, it has
been supposed that BAFF might be a good therapeutical
target in this disease; actually a fully human anti-human
BAFF monoclonal antibody that neutralizes the activity
of BAFF protein (Belimumab, Lympho-Stat-B) was
used in a phase clinical I trial in SLE patients (n=70).
Patients were randomized to receive 1, 4, 10, or 20 mg/
kg versus placebo with a single intravenous (IV) dose or
2 infusions 21 days apart. This treatment was well
tolerated, but showed modest clinical effects: peripheral
blood CD20pos B-cell counts dropped by 12–47% with-
out any change in anti-dsDNA antibody concentration
or disease activity [11,12]. In the meantime other mole-
cules were generated to target the BAFF pathway and
are strong candidates to be used in clinical trials for
SLE, for example, the fusion proteins TACI–Ig and
BR3–Fc and the “peptibody” AMG623 all functioning
as BAFF antagonists [13]. Importantly, TACI (that
probably acts as a negative regulator of B cell) binds
also a BAFF related ligand called APRIL, increased in
some autoimmune disorders [14]. The role that each of
these molecules might play in disease is not fully
understood. Because TACI–Ig [15] is able to neutralize
both BAFF and APRIL, the use of this molecule might
have a higher clinical efficiency than the anti-BAFF
Belimumab alone.
3. Lack of B cell tolerance/altered B cell selection
In the last years a developing awareness of the central
role of B-lymphocytes in SLE has brought to the hy-
pothesis that the disease may be caused by failure of
tolerance induction. The induction of tolerance is neces-
sary to purge the peripheral repertoire of dangerous
specificities, that arise by the random rearrangement of
heavy and light chain immunoglobulin genes and by the
unrestrained assembly of their products. The elimination
of these specificities occurs by negative selection, a
phenomenon has is thought to occur during the early
phases of B cell development in the bone marrow and inthe periphery when transitional B cells differentiate in
mature/memory. Negative selection occurs by the forced
replacement of the light chain (editing) [16] or by the
induction of cell death (clonal deletion) [17]. Generation
of auto-reactive B cells in SLE can be a consequence of
a failure of negative selection in the bone marrow. Thus,
several attempts have been done with the idea of re-
moving all autoreactive cells and their precursors and
“resetting” the system. Hematopoietic stem cell trans-
plantation has been recognised as a potential treatment
in SLE patients that failed to respond to conventional
therapy. After a series of unsuccessful allogenic trans-
plantations [18], autologous donor cells reconstitution
has been implemented. Although, with different modal-
ities of BM ablation, the latter has given encouraging
clinical results, but further studies are needed to support
its use as a common therapeutic approach for SLE [19].
Another strategy is the induction of a massive B cell
depletion by directly targeting surface molecules only
expressed by B cells. One candidate target is the CD20
molecule. CD20 is a 33- to 37-kDa non-glycosylated
tetraspan phosphoprotein calcium-channel that is ex-
pressed in all B cells, with the exception of pro-B in the
BM and plasma cells. Rituximab (RTX) is an anti-CD20
humanized mAb that causes B cell depletion by at least
three mechanisms: antibody-dependent cell-mediated
cytotoxicity, complement-dependent cytotoxicity and
apoptosis. Rituximab was successfully used in non-
Hodgkin B cell lymphoma before its introduction in the
therapy of autoimmune disorders.
The first data showing the efficacy of RTX treatment
in patients with SLE comes from open label trials pub-
lished by Looney at al in 2002 [20]. In this Phase I/II
trial 18 patients with clinically active non-organ-in-
volving SLE were treated with a low (100 mg/m2),
medium (375 mg/m2) and full dosage (4 weekly doses
of 375 mg/m2). All patients showed a significant pe-
ripheral B cell depletion that correlated with the reduc-
tion of disease activity, but without significant changes
in anti-dsDNA antibody levels [21]. Moreover, several
groups have treated patients with lupus nephritis re-
fractory to CyC, with a combination of CyC and RTX
obtaining very promising results. In one of these studies,
renal biopsy performed before and after the therapy,
revealed an improvement in 5/5 cases of active ne-
phritis. Also, Sfikakis and colleagues documented a
successful renal response in 8/10 (5/10 complete re-
mission) patients with proliferative lupus nephritis [22].
Efficacy of RTX therapy in SLE patients with com-
promised central nervous system has also been evalu-
ated. Its use as monotherapy or in combination with
CyC resulted in clinical improvement in 72% of 22
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remained stable [23].
CD22 is a 135-kDa B-lymphocyte restricted type-I
transmembrane sialoglycoprotein of the immunoglobu-
lin (Ig) superfamily. It is first detectable at low levels in
immature B cells, its strongly expressed on mature B
cells and absent in plasma cells. In mouse, lack of CD22
expression has been shown to decrease the threshold of
BCR reactivity and thus potentially increase BCR de-
pendent B cell activation and antibody production.
CD22, therefore, appeared to be a good candidate as a
target of therapy in B-cell dependent autoimmune dis-
orders. Epratuzumab (hLL2) is a humanized IgG1
monoclonal antibody against CD22 antigen that has
been recently tested in an open-label, pilot study of 14
active SLE patients. Epratuzumab showed to be safe and
effective. It gave very promising results: the majority of
patients treated during phaseI/II trial experienced a 50%
improvement in the BILAG (British Isles Lupus
Assessment Group) score and a phase III lupus trial is
ongoing [24].
4. T-B cell crosstalk and SLE
In humans, high-affinity antibodies are generated
through an extensive process of hypermutation and af-
finity maturation that takes place in specialised struc-
tures called germinal centers (GC). GC are composed of
follicular dendritic cells, B and T cells that come to-
gether in response to foreign antigens and results on the
generation of high affinity class-switched memory B
cells and plasma cells [25]. In autoimmune disorders the
GC develops against self-antigens and generates mem-
ory B-cells expressing an autoreactive BCR repertoire.
As this repertoire is probably already established at the
time when the disease is diagnosed, targeting the ger-
minal center in SLE has been taken with certain scep-
ticism. However, as we still don't know whether GC are
required for the continuous supply of auto-reactive
plasma cells, antibodies targeting co-stimulatory signal-
ling pathways able to interfere with T-B cell interactions
have been launched in SLE clinical trials [26].
B cells, binding through CD40 to CD154 (CD40L)
on T cells receive one of the most important co-stimu-
latory signals resulting in activation, proliferation, and
Ig class switching in the germinal centre environment.
Anti-CD40L monoclonal antibody (Biogen Hu5c9 anti-
body) has been used in two designed studies on SLE
patients with and without renal involvement. Despite the
encouraging results, improvement of renal function and
reduction in circulating autoantibodies, the trial had to
be abandoned because all patients suffered of lifethreatening thrombotic episodes. These vascular side
effects were most probably due to the binding of the
Biogen Hu5c9 antibody to platelets leading to massive
aggregation [27–29].
Another co-stimulatory axis is composed of CD28,
expressed by T cells, and B7 ligands on activated B
cells. The interaction results in T cell activation, prolif-
eration and up-regulation of. CTLA-4 (cytotoxic T-
lymphocyte-associated protein 4). CTLA4 binds to B7
with higher affinity than CD28 and switches-off the
activation signals delivered through the T-cell receptor.
CTLA4Ig is a recombinant fusion protein composed
of an extracellular domain of CTLA and a constant
region human immunoglobulin (Abatacept, Orencia;
Bristol-Myers Squibb). Abatacept has been used with
success in rheumatoid arthritis (RA) [30] and psoriasis
and is currently being tested, associated with CyC, in a
preliminary trial in SLE patients.
5. Cytokine therapy
Recently, it became apparent that the cytokine milieu
is important in triggering and sustaining autoimmune
disorders. In fact, in SLE patients levels of circulating
type I interferon (IFN-α), IL-6 and IL-10 are increased.
The exacerbated production of these inflammatory cyto-
kines is the result of the abnormal activation of plasma-
cytoid dendritic cells [31]. IFN-α can be involved in
the pathogenesis of lupus in multiple ways [32]. It
triggers the maturation of myeloid dendritic cells there-
by enhancing the adaptive immune response, and, in
combination with CD40, induces plasmablast differen-
tiation. IL-6 is thought to be indispensable for the final
differentiation of plasmablasts to plasma cells [33,34].
Waiting for an approved IFN-blocking therapy, anti-IL-
6 antibodies have been used in mouse models in which
induced experimental nephritis could be delayed by IL-6
blockade. An anti-IL6R monoclonal antibody (Tocili-
zumab) has been approved for use in a human phase I
clinical trial. The role of IL-10 in SLE pathogenesis is
not very clear [35]. IL-10 is considered a regulatory/
tolerogenic cytokine, because it inhibits monocyte and
dendritic cell pro-inflammatory function and promotes
the differentiation of regulatory T cells (Treg). In B cells
it induces activation, differentiation and antibody pro-
duction. In SLE patients the concentration of IL-10
correlates with disease activity. Ronnelid et al have
showed that immune complexes isolated from SLE
patients are able to induce IL-10 production in PBMC
from healthy donors suggesting the involvement of IL-
10 in the vicious cycle that maintain B cell hyperactivity
and antibody secretion [36].
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used in a pilot trial involving 6 SLE patients. After three
weeks of daily treatment 5/6 patients showed skin and
joint improvement and at 6 months disease activity was
strongly reduced (as measured with SLEDAI score). At
the end of the follow-up all patients had developed
antibodies against the murine MoAb but no significant
side effects were reported [37].
6. Targeting autoantibodies
In SLE, like in several other autoimmune diseases,
autoantibodies may be detectable in the serum many
years before the onset of the clinical manifestations. It
has been hypothesized that the first clinical symptoms
appear either when the concentration of autoantibodies
exceeds a certain threshold or when highly pathogenic
specificities are produced. We know that not all auto-
antibodies are equal. In the mouse autoantibodies such as
anti-Ro, anti-b2-glycoprotein I, anti-erythrocytes and
anti-platelets have shown to be pathogenic once pas-
sively transferred through the placenta or injected in
adult animals. Autoantibodies in immune complexes are
responsible for the general activation of the inflamma-
tory cascade not only via complement but also stimu-
lating Toll-like receptors pathway.
Tolerogens by definition are synthetic agents that
deplete or inactivate autoreactive B cells by binding to-
and cross-linking autoantibodies. The tolerogen,
LJP394, is a scaffold of a polyethylene glycol platform
with attached DNA that selectively clears DNA-reactive
autoantibodies in SLE. They form soluble complexes
with the autoantibodies without activating the comple-
ment cascade, thus preventing renal damage. LJP394
(Abetimus sodium, Riquent) was introduced in 1994 in
human trials. The successful results obtained in some of
the first 13 trials were confirmed with an enlarged phase
III study. The treatment with Abetimus of SLE patients
with lupus nephritis and elevated dsDNA antibodies
resulted in sustained and significant decrease in anti-
dsDNA antibody levels, reduced incidence of renal flares
and improvement of health-related quality of life. In a
group of lupus nephritis patients the reduction in anti-
dsDNA levels was transient and no significant clinical
benefits were observed [38].
7. Conclusions and perspectives
Therapy for lupus disease could be greatly improved
by the use of ‘biologic’ drugs in combination with the
traditional immunosuppressants, specially in patients
refractory to monotherapy. Few studies have given en-couraging result, but larger clinical trials are needed in
order to have a clear picture of the balance benefits/risks.
Although biologic drugs represent an enormous step
forward in the treatment of autoimmune disorders, we
are still far from being able to target only auto-aggressive
B-cells. As consequence the risk of infection is always
present and has to be considered before any therapy.
Humanized antibodies became very fashionable and
wildly used, but one should keep in mind that these
molecules have two serious drawbacks. First, chimeric
antibodies contain a foreign component and such can be
immunogenic [39]. Second, the potential pathogenic B
cells that do not express the receptors or express it at low
levels are not affected by the antibody treatment.
Take-home messages
• B cells have a pivotal role in SLE. Animal models and
human studies recently identified multiple abnor-
malities in the B cell physiology (altered frequency of
B cell subsets, break of B cell tolerance and hyper-
reactivity) in SLE, providing the rationale to introduce
B cell targeted biologic drugs in therapeutical regimens.
• The safety and efficacy of Rituximab, Epratuzumab,
Riquent and TACI–Ig usage in SLE has been demon-
strated during the first clinical trials. Many other mole-
cules are included in pre-clinical studies, after the
successful results obtained in mouse models and
primate.
• Despite the encouraging results obtained with bio-
logic drugs, a category of SLE patients remain un-
responsive to all treatments. For these patients we can
envisage a combined regimen including either immu-
nosuppression and biologic drugs or a combination
of biologic drugs targeting distinct branches of B cell
physiology.
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